When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.
Be alerted of any news about your stocks and see what other stocks are trending.
CCXI - ChemoCentryx: Revisiting The Investment Case
ChemoCentryx Inc.
Today, we revisit a biopharma concern called ChemoCentryx for the first time since late in 2021.
The company is in the initial rollout of its primary product TAVNEOS, which is approved for one indication and in development for three other diseases.
ChemoCentryx has a solid balance sheet and analyst firms are modeling explosive revenue growth ahead for the company.
An investment analysis follows in the paragraphs below.